US 10968222
2-azabicyclo hexane JAK inhibitor compound
granted A61KA61K9/0019A61K9/0048
Quick answer
US patent 10968222 (2-azabicyclo hexane JAK inhibitor compound) held by Theravance Biopharma R&D IP, LLC expires Mon Apr 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Theravance Biopharma R&D IP, LLC
- Grant date
- Tue Apr 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 15
- CPC classes
- A61K, A61K9/0019, A61K9/0048, A61P, A61P27/02